Agoracom: Small Cap Investment - Resverlogix Corp. - Another application/indicati... for the compound libraries

...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Reply New Message

Back To Forum List View

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Another application/indicati... for the compound libraries

posted on May 19, 2017 12:01PM

Selective BET bromodomain inhibition as an antifungal therapeutic strategy

https://www.ncbi.nlm.nih.gov/pubmed/28516956

Candida albicans is a major human fungal pathogen. Resverlogix and Zenith have thousands of compounds in their small molecule libraries. Several of these may be able to discriminate CaBdf1 from human BET bromodomain proteins.

"These findings establish BET inhibition as a promising antifungal therapeutic strategy and identify Bdf1 as an antifungal drug target that can be selectively inhibited without antagonizing human BET function."

"In summary, CaBdf1 and human BET BDs have distinct BETi-binding activity, supporting the feasibility of targeting CaBdf1 BDs with highly selective small-molecule inhibitors."